Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX)

CUSIP: 22663K107

Q4 2021 13F Holders as of 31 Dec 2021

Holder snapshot 6 signals
Share change
+8,733,372
SEC-reported price per share
$28.41
Number of holders
114
Value change
+$251,517,738
Number of buys
83
Number of sells
24
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
105,000,216

Security key

22663K107

Report period

Q4 2021

Institutions

114

Top holders

10

Ownership snapshot

Top reported holders of CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
30 Sep 2021
13F Lead comparable stake: 4.2% Showing 1-6 of 15 holder rows.

Quick read

FMR LLC leads the comparable SEC ownership view at 4.2%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FMR LLC's linked filing trail.
Comparable ownership Top 5
FMR LLC 4.2%
PERCEPTIVE ADVISORS LLC 3.8%
DRIEHAUS CAPITAL MANAGEMENT LLC 2.9%
ORBIMED ADVISORS LLC 2.9%
BlackRock Finance, Inc. 2.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FMR LLC
13F
Company
13F
4.2%
$93,177,000
4,426,434 shares
30 Sep 2021
PERCEPTIVE ADVISORS LLC
13F
Company
13F
3.8%
$83,432,000
3,963,517 shares
30 Sep 2021
DRIEHAUS CAPITAL MANAGEMENT LLC
13F
Company
13F
2.9%
$63,119,000
2,998,512 shares
30 Sep 2021
ORBIMED ADVISORS LLC
13F
Company
13F
2.9%
$63,084,000
2,996,876 shares
30 Sep 2021
BlackRock Finance, Inc.
13F
Company
13F
2.5%
$55,084,000
2,616,839 shares
30 Sep 2021
Bain Capital Life Sciences Investors, LLC
13F
Company
13F
1.6%
$35,358,000
1,679,701 shares
30 Sep 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
114
Shares
44,273,322
Rows available
114
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2021 vs Q3 2021 Across Filers

Q3 2021 holders
91
Q4 2021 holders
114
Holder diff
23
Investor Q3 2021 Shares Q4 2021 Shares Share Diff Share Chg % Q3 2021 value Q4 2021 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .